These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32399853)

  • 1. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Shinde A; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2020 Jul; 40(7):603-615. PubMed ID: 32399853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
    Nirogi R; Benade V; Daripelli S; Subramanian R; Kamuju V; Bhyrapuneni G; Muddana NR; Mekala VR; Petlu S; Jayarajan P; Badange R; Shinde A; Jasti V
    Psychopharmacology (Berl); 2021 Jun; 238(6):1495-1511. PubMed ID: 33550481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT
    Nirogi R; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2021 May; 41(5):469-482. PubMed ID: 33788154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H
    Nirogi R; Bhyrapuneni G; Muddana NR; Manoharan A; Shinde AK; Mohammed AR; Padala NP; Ajjala DR; Subramanian R; Palacharla VRC
    Eur J Pharm Sci; 2020 Sep; 152():105425. PubMed ID: 32534194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Palacharla RC
    Clin Drug Investig; 2018 May; 38(5):401-415. PubMed ID: 29380267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LC-MS/MS method for the quantification of SUVN-G3031, a novel H3 receptor inverse agonist for narcolepsy treatment.
    Nirogi R; Ajjala DR; Prakash Padala NS; Kalaikadhiban I; Rayapati LP; Chunduru P; Shinde A
    Bioanalysis; 2020 Apr; 12(8):533-544. PubMed ID: 32351118
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
    Nirogi R; Benade V; Goyal VK; Pandey SK; Mohammed AR; Shinde A; Dogiparti D; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2022 Sep; 42(9):747-762. PubMed ID: 35963959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H
    Nirogi R; Shinde A; Mohammed AR; Badange RK; Reballi V; Bandyala TR; Saraf SK; Bojja K; Manchineella S; Achanta PK; Kandukuri KK; Subramanian R; Benade V; Palacharla RC; Jayarajan P; Pandey S; Jasti V
    J Med Chem; 2019 Feb; 62(3):1203-1217. PubMed ID: 30629436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.
    Othman AA; Haig G; Florian H; Locke C; Zhang J; Dutta S
    Br J Clin Pharmacol; 2013 May; 75(5):1299-311. PubMed ID: 23016924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
    Muehler A; Kohlhof H; Groeppel M; Vitt D
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):557-573. PubMed ID: 32361977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects.
    Matsuno K; Kuroda S; Tanaka S; Nakamichi H; Kagawa T; Koumura E
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):607-614. PubMed ID: 29845723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
    Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
    J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.
    Othman AA; Lenz RA; Zhang J; Li J; Awni WM; Dutta S
    J Clin Pharmacol; 2011 Apr; 51(4):512-26. PubMed ID: 20495134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
    Zhu Y; Statkevich P; Cutler DL
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):539-47. PubMed ID: 17966839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.